Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenchen Yu

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccinesCassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
Vaccine|July 7, 2021
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest periodYunda Huang, Kelly E Seaton, Martin Casapia, et al.
The Lancet. HIV|October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trialMagdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccinesCassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
Vaccine|July 7, 2021
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest periodYunda Huang, Kelly E Seaton, Martin Casapia, et al.
The Lancet. HIV|October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trialMagdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Plos Medicine|February 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccinesFatima Laher, Zoe Moodie, Kristen W Cohen, et al.
PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Pageof 8